2500003M10Rik Inhibitors
Chemical inhibitors of 2500003M10Rik utilize various mechanisms to modulate the activity of this protein by targeting different kinases and signaling pathways involved in its regulation. Staurosporine, a broad-spectrum kinase inhibitor, can suppress the activity of a wide range of kinases that phosphorylate 2500003M10Rik, thereby preventing its activation. In a similar vein, Dasatinib, which selectively inhibits Src family kinases and Abl, can impede the signaling cascades necessary for the proper functioning of 2500003M10Rik. Sorafenib and Sunitinib, both targeting multiple receptor tyrosine kinases including VEGFR and PDGFR, can disrupt the phosphorylation process essential for the activity of 2500003M10Rik.
In addition to these, Erlotinib and Gefitinib specifically target the EGFR tyrosine kinase, which can be an upstream regulator of 2500003M10Rik within certain signaling pathways. By inhibiting EGFR, these inhibitors can prevent the subsequent activation of 2500003M10Rik. Furthermore, Rapamycin, by forming a complex with FKBP12, inhibits mTOR, which is potentially a key kinase in the cell growth and proliferation pathways that might regulate 2500003M10Rik. LY294002, as a PI3K inhibitor, halts the PI3K/Akt pathway that can be crucial for the regulation of 2500003M10Rik. PD98059 and U0126, both MEK inhibitors, can halt the MAPK/ERK pathway, which, if 2500003M10Rik is a downstream component, will result in the inhibition of this protein's function. Lastly, SB203580 and SP600125, which target p38 MAP kinase and JNK respectively, are capable of inhibiting the activity of 2500003M10Rik if it is a part of the pathways regulated by these kinases. These chemical inhibitors, by targeting these specific kinases and pathways, can effectively modulate the functional activity of 2500003M10Rik.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $150.00 $388.00 | 113 | |
Staurosporine is a potent, non-selective inhibitor of protein kinases. It inhibits many kinases that could phosphorylate 2500003M10Rik, thereby preventing its activation or rendering it inactive. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $47.00 $145.00 | 51 | |
Dasatinib is a selective inhibitor of the Src family kinases and Abl. By inhibiting these kinases, Dasatinib could inhibit downstream signaling that may be necessary for the functional activity of 2500003M10Rik. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $56.00 $260.00 $416.00 | 129 | |
Sorafenib is a kinase inhibitor that targets several receptor tyrosine kinases, including VEGFR and PDGFR. By inhibiting these receptors, Sorafenib can inhibit signaling pathways that 2500003M10Rik is involved in, leading to its functional inhibition. | ||||||
Sunitinib, Free Base | 557795-19-4 | sc-396319 sc-396319A | 500 mg 5 g | $150.00 $920.00 | 5 | |
Sunitinib is a receptor tyrosine kinase inhibitor, which targets PDGFR and VEGFR among others. It can inhibit the phosphorylation of 2500003M10Rik by these kinases, which is crucial for its function. | ||||||
Erlotinib, Free Base | 183321-74-6 | sc-396113 sc-396113A sc-396113B sc-396113C sc-396113D | 500 mg 1 g 5 g 10 g 100 g | $85.00 $132.00 $287.00 $495.00 $3752.00 | 42 | |
Erlotinib specifically inhibits EGFR tyrosine kinase, which could be upstream of 2500003M10Rik in a signaling pathway. By inhibiting EGFR, Erlotinib would inhibit the activation of 2500003M10Rik. | ||||||
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $62.00 $112.00 $214.00 $342.00 | 74 | |
Gefitinib inhibits EGFR tyrosine kinase, and if 2500003M10Rik is part of the EGFR signaling pathway, this inhibition would result in the functional inhibition of 2500003M10Rik. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin binds to FKBP12 and together they inhibit mTOR, a kinase involved in cell growth and proliferation. Inhibition of mTOR can lead to inhibition of 2500003M10Rik if it is involved in mTOR signaling pathways. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is an inhibitor of PI3K, which is involved in the Akt pathway. Since PI3K signaling can regulate multiple proteins, inhibiting PI3K can inhibit downstream proteins like 2500003M10Rik. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD98059 is a selective inhibitor of MEK, which acts upstream of ERK in the MAPK pathway. Inhibition of MEK can lead to inhibition of 2500003M10Rik if it is regulated by the MAPK pathway. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
U0126 also inhibits MEK, preventing the activation of the ERK pathway. If 2500003M10Rik functions downstream of this pathway, its activity would be inhibited by U0126. | ||||||